1,633 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AMGN Amgen Inc. $200.81 $129.98B Uptrend
Article Searches
Merck's Keytruda Fails to Meet Endpoint in Liver Cancer Study http://www.zacks.com/stock/news/355533/mercks-keytruda-fails-to-meet-endpoint-in-liver-cancer-study?cid=CS-ZC-FT-355533 Feb 20, 2019 - Merck's (MRK) Keytruda fails a phase III study in second-line advanced hepatocellular carcinoma (HCC). It gets FDA approval for the adjuvant treatment of patients with high-risk stage III melanoma.
Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review http://www.zacks.com/stock/news/355489/roches-rhhby-bla-for-lymphoma-drug-gets-priority-review?cid=CS-ZC-FT-355489 Feb 19, 2019 - The FDA accepts Roche's (RHHBY) BLA for polatuzumab vedotin and NDAs for entrectinib, and grants Priority Review status to the applications.
What Are The Highest Quality Dividend Growth Stocks? https://seekingalpha.com/article/4242014-highest-quality-dividend-growth-stocks?source=feed Feb 19, 2019 - Many dividend growth investors seek the highest-quality companies.Independent data providers such as S&P, Morningstar, and Simply Safe Dividends offer rankings of quality factors.A simple scoring syst
Merck Gets Priority Review for Keytruda Combo in Kidney Cancer http://www.zacks.com/stock/news/355193/merck-gets-priority-review-for-keytruda-combo-in-kidney-cancer?cid=CS-ZC-FT-355193 Feb 18, 2019 - Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.
Regeneron and Sanofi prevail in review of Amgen's IL-4 receptor patent https://seekingalpha.com/news/3434167-regeneron-sanofi-prevail-review-amgens-ilminus-4-receptor-patent?source=feed_news_all Feb 16, 2019 - Regeneron Pharmaceuticals (NASDAQ:REGN) and development partner Sanofi (NASDAQ:SNY) announce that the USPTO has invalidated 17 claims as obvious of U.S. Patent No. 8,679,487 owned by Amgen's (NASDAQ:A
Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down http://www.zacks.com/stock/news/354559/teva-teva-q4-earnings-miss19-view-weak-shares-down?cid=CS-ZC-FT-354559 Feb 14, 2019 - Teva's (TEVA) fourth-quarter earnings miss estimates while sales marginally beat expectations. Guidance for 2019 is lower than expected.
Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report http://www.zacks.com/stock/news/354373/key-takeaways-from-eli-lillys-lly-q4-earnings-report?cid=CS-ZC-FT-354373 Feb 13, 2019 - Here are the key takeaways from Eli Lilly's (LLY) fourth-quarter earnings conference call.
Amgen teams up with Abilita Bio in drug discovery https://seekingalpha.com/news/3432773-amgen-teams-abilita-bio-drug-discovery?source=feed_news_all Feb 13, 2019 - Amgen (AMGN) will collaborate with privately held Abilita Bio to discover new drugs that target complex membrane proteins by leveraging the latter's Enable Membrane Protein (EMP) platform.Acco
Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer http://www.zacks.com/stock/news/353843/mercks-keytruda-gets-fda-priority-review-for-head-neck-cancer?cid=CS-ZC-FT-353843 Feb 12, 2019 - Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma http://www.zacks.com/stock/news/353842/abbvie-buys-rights-to-novel-immunotherapy-for-multiple-myeloma?cid=CS-ZC-FT-353842 Feb 12, 2019 - AbbVie (ABBV) enters a global strategic transaction agreement with privately-held Teneobio to develop and commercialize the latter's pre-clinical immunotherapy candidate, TNB-383B, as a multiple myeloma treatment.

Pages: 12345678...164

<<<Page 3>